
Binds to RANKL
Binds to sclerostin
T366W/
S354C:T366W/
Y349C:T366W
T366S:L368A:Y407V/
Y349C:T366S:L368A:Y407V/
S354C:T366S:L368A:Y407V
Binds to sclerostin
Binds to RANKL
T366W/
S354C:T366W/
Y349C:T366W
T366S:L368A:Y407V/
Y349C:T366S:L368A:Y407V/
S354C:T366S:L368A:Y407V

FIG.1A



FIG.1B



	Denosumab	DR-P7	DR-P15	DR-P16
EC_{50} (μg/mL)	0.05043	0.1153	0.04576	0.4904



	Romosozumab	DR-P7	DR-P15	DR-P16
EC_{50} (μg/mL)	0.08375	0.09079	0.506154	0.00419

FIG.2


Number of TRACP+ cells (#)
200
150
100
50
0
-50
100
10
1
0.1
0.01
0.001
0.0001
conc. [μg/mL]
Denosumab
DR-P7
DR-P8

FIG.3


hMMP9
hFATc1
hAcp5
hCTSK
Relative expression (a.u.)
Negative
hRANKL
hRANKL + Deno
hRANKL + DR-P7
hRANKL + DR-P8
hRANKL + IgG2

FIG.4


80
60
40
20
0
-20
-40
% inhibition
Romosozumab IC50:18.94
DR-P7 IC50: 26.88
DR-P8 IC50: 24.92
Denosumab IC50: NA
hIgG2 IC50: NA
0.1
1
10
100
Molarity (nM)

FIG.5


3.5
3.0
2.5
2.0
1.5
1.0
Tb.N (1/mm)
1.0
0.8
0.6
0.4
0.2
0.0
Tb.Sp (mm)
Control
OVX + IgG
OVX + Romo
OVX + Deno
OVX + DR-P7

FIG.6